Table 5.
Clinical outcomes between hyperbilirubinemia and non-hyperbilirubinemia groups after propensity score matching.
| Parameters | Full cohort | P | |
|---|---|---|---|
| Hyperbilirubinemia group | No-hyperbilirubinemia group | ||
| (n = 532) | (n = 532) | ||
| Serum total bilirubin levels during the course of disease (mg/dL), n (%) | <0.001 | ||
| Serum total bilirubin at 0–1.9 mg/dL | 0 (0) | 532 (100.0) | |
| Serum total bilirubin at 2–4.9 mg/dL | 333 (62.6) | 0 | |
| Serum total bilirubin at 5–10 mg/dL | 139 (26.1) | 0 | |
| Serum total bilirubin at >10 mg/dL | 60 (11.3) | 0 | |
| The life support | |||
| Vasopressor usage, n (%) | 242 (45.5) | 222 (41.7) | 0.240 |
| Mechanical ventilation, n (%) | 267 (50.2) | 263 (49.4) | 0.854 |
| Sedative drug usage | 265 (49.8) | 248 (46.6) | 0.326 |
| AKI KDIGO stage, n (%) | 0.110 | ||
| AKI at 1 stage | 117 (22.0) | 176 (23.1) | |
| AKI at 2 stage | 167 (31.4) | 132 (24.8) | |
| AKI at 3 stage | 95 (17.9) | 101 (19.0) | |
| Clinical outcomes | |||
| In-hospital mortality, n (%) | 85 (16.0) | 63 (11.8) | 0.036 |
| 30 d mortality, n (%) | 114 (21.4) | 89 (16.7) | 0.038 |
| 90 d mortality, n (%) | 133 (25.0) | 104 (19.5) | 0.027 |
| 180 d mortality, n (%) | 143 (26.9) | 120 (22.6) | 0.066 |
| One-year mortality, n (%) | 157 (29.5) | 130 (24.4) | 0.047 |
Categorical variables are reported as count (% of column total).
AKI acute kidney injury, KDIGO the Kidney Disease: Improving Global Outcomes.